Cat# : THA-0149
Cat#: | THA-0149 |
Product Name: | Axatilimab |
Description: | Axatilimab is a monoclonal antibody targeting CSF-1R to reduce pathogenic macrophage activity in patients with chronic graft-versus-host disease. |
Sequences: | axatilimab_heavy_chain: EVTLKESGPALVKPTQTLTLTCTFSGFSLTTYGMGVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIGPIKYPTAPYRYFDFWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK axatilimab_light_chain: DIQMTQSPSSLSASVGDRVTITCLASEDIYDNLAWYQQKPGKAPKLLIYYASSLQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQDSEYPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Molecular Weight: | 150000.0 Da |
Introduction: | Axatilimab is a humanized IgG4 monoclonal antibody produced in Chinese hamster ovary cells. It is targeted against macrophage colony-stimulating factor 1 receptor (CSF-1R), causing a reduction in circulating levels of monocytes and macrophages responsible for the symptoms associated with chronic graft-versus-host disease (cGVHD). The mainstay of cGVHD treatment are systemic corticosteroids, but they are ineffective in 30-50% of cases. Approved treatment options in steroid-refractory cGHVD are limited, and include ruxolitinib, ibrutinib, and belumosudil. Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD. It is the first FDA-approved anti-CSF-1R antibody directed against inflammatory and fibrotic drivers in chronic graft-versus-host disease. |
Purity: | >99% by SDS-Page and HPLC analysis |
Formula: | Not Available |
Appearance: | Liquid |
For more information on how our products could help advance your project, please contact us.
ENTER YOUR EMAIL HERE TO SUBSCRIBE.
Copyright © 2024 Creative BioMart. All Rights Reserved.